肿瘤资讯 | 患者指南 | 肿瘤专科互联网医院

首页 > 文章详情

【第五届35under35初赛作品】III期肺腺癌术后复发转移免疫治疗病例分析

2021年05月31日

作者：韩飞

医院：西南医科大学附属医院

韩飞

医师

参考文献

[1] Mok TSK，Wu YL，Kudaba I，et al. Pembrolizumab versus chemotherapy for previously untreated，PD-L1-expressing,locally advanced or metastatic non-small-cell lung cancer(KEYNOTE-042)：a randomised，open-label，controlled，phase 3 trial[J]. Lancet,2019,393(10183)：1819-1830.

[2] Langer CJ，Gadgeel SM，Borghaei H，et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced,non-squamous non-small-cell lung cancer：a randomised,phase 2 cohort of the open-label KEYNOTE-021 study[J].Lancet Oncol,2016,17(11):1497-1508.

[3] Yang Haitang,Hall Sean R R,Yao Feng,The Value of PD-L1 Expression in Metastatic Lymph Nodes of Advanced Non-Small Cell Lung Cancer.[J] .Chest, 2020, 158: 1785-1787.

[4] 闫相涛,王慧娟,李鹏,张国伟,杨金坡,牛媛媛,张米娜,张晓娟,马智勇. 免疫治疗后进展的晚期非小细胞肺癌二线继续免疫治疗联合化疗的回顾性分析[J]. 肿瘤学杂志,,:1-5.

[5] Wu YL，Lu S，Cheng Y，et al. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC：Check Mate 078 Randomized Phase Ⅲ Clinical Trial[J]. J Thorac Oncol,2019,14(5):867-875.